Articles

Find an Article

Filter articles

Applied Filters

Showing 1 to 10 of 314 results

Event preview: Life Sciences IP Due Diligence summit

US22-10-2019

The Annual Summit on Life Sciences IP Due Diligence to be held on November 14 and 15 in Boston, MA, is a one-of-a-kind, interactive forum where diligence experts discuss best practices and strategies for executing a proper IP due diligence analysis for incumbent portfolios and those of potential targets.

Medicinal Cannabis: what next for Brazil?

Brazil21-10-2019Ludmila Kawakami and Ana Paula Couto

Tensions between public use, drug laws and regulators make IP around Cannabis a complex situation, explains Ludmila Kawakami and Ana Paula D. C. Couto of Di Blasi, Parente & Associados.

Conference preview: LSX World Congress USA

04-10-2019Paul Gilbertson

LSX World Congress USA brings life sciences investment and partnering to Boston.

Pharma: A Mexican tradeoff

Mexico30-09-2019Margarita Guerrero Gonzalez

While providing benefits to Mexico’s biologics system, the USMCA may also increase costs for citizens, argues Margarita Guerrero Gonzalez of Uhthoff, Gomez Vega & Uhthoff.

Divisional applications: Procedural manoeuvres pay off

Brazil30-09-2019Kene Gallois and Luis Felipe Maciel da Silva

Filing a divisional patent application in Brazil needs a keen understanding of the process and flexibility in the system, as Kene Gallois and Luis Felipe Maciel da Silva of Daniel Law explain.

Conference preview: Women Leaders in Life Sciences Law

US26-06-2019

The next event in ACI’s Women Leaders in Law series, on July 25 & 26 in Boston, brings together in-house and private practice professionals from the pharmaceutical, biotechnology, and medical device industries.

Marketing authorisation: Splitting the bill

US20-05-2019Mark Remus

An increasing number of pharmaceutical companies are turning to joint representation—where they pool their funds and hire one firm to represent them all—for ANDA litigation. Mark Remus, shareholder at Brinks Gilson & Lione, outlines the pros and cons of this new direction.

The heart of the 3D printing matter

US20-05-2019Gabriel Di Blasi

3D-printed organs and tissues are now a reality, but questions remain over their patentability, says Gabriel Di Blasi of Di Blasi, Parente & Associados.

Creative solutions for cannabis industry IP

US20-05-2019Leon Steinberg

While registering trademarks for cannabis products at the USPTO is currently impossible, brands are applying creative solutions to the problem, says Leon Steinberg of Dennemeyer.

Antibody patents: Danger ahead for biologics

US20-05-2019John H. Heithaus and Gerald M. Murphy

The evolution of antibody written description standards at the USPTO has put some drug portfolios at risk, say John Heithaus and Gerald Murphy of Birch, Stewart, Kolasch & Birch.

Showing 1 to 10 of 314 results

LSIPR